Dateline City:
KENILWORTH, N.J.
Updated Findings with Longer Follow-Up in Classical Hodgkin Lymphoma to be Featured in Oral Presentations
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data regarding the investigational use of
KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy,
in patients with a range of blood cancers including classical Hodgkin
lymphoma and primary mediastinal large B-cell lymphoma, will be
presented at the 58th Annual Meeting of the American Society of
Hematology (ASH) in San Diego, Dec. 3-6.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more